A brain cancer vaccine developed at Roswell Park Comprehensive Cancer Center appears to be safe and significantly extends survival in newly diagnosed glioblastoma patients, according to a Phase 2A single-arm clinical trial. The study, “Phase 2A Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma,” appears this week in the Journal of Clinical Oncology. Manmeet Ahluwalia, MD, MBA, Fernandez Family Foundation Endowed Chair in Cancer Research, Chief of Medical Oncology, Deputy Director and Chief Scientific Officer of Miami Cancer Institute, served as overall Principal Investigator.